Cargando…
Safety of Early Bevacizumab Administration after Central Venous Port Placement for Patients with Colorectal Cancer
SIMPLE SUMMARY: The safety of bevacizumab administration immediately after central venous (CV) port placement, a minor surgery, is still unknown. We investigated whether Bevacizumab is safe when administered early after CV port placement. Bevacizumab therapy after CV port implantation did not affect...
Autores principales: | Shigyo, Hirona, Suzuki, Hiroyuki, Tanaka, Toshimitsu, Moriyama, Etsuko, Shimotsuura, Yasutaka, Nagasu, Sachiko, Iwamoto, Hideki, Akagi, Yoshito, Murotani, Kenta, Kawaguchi, Takumi, Miwa, Keisuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137085/ https://www.ncbi.nlm.nih.gov/pubmed/37190192 http://dx.doi.org/10.3390/cancers15082264 |
Ejemplares similares
-
Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
por: Tanaka, Toshimitsu, et al.
Publicado: (2022) -
Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer
por: Moriyama, Etsuko, et al.
Publicado: (2023) -
Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancer
por: Tanaka, Toshimitsu, et al.
Publicado: (2022) -
Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016) -
Comparison of long-term quality of life based on surgical procedure in patients with rectal cancer
por: Yuge, Kotaro, et al.
Publicado: (2023)